title: The predictive role of E-cadherin and androgen receptor on in vitro chemosensitivity in triple-negative breast Cancer.
abstract: OBJECTIVE
  The purpose of this study was to evaluate the impact of various pathologic and biologic factors in triple-negative breast cancer (TNBC) on chemotherapy response using in vitro ATP-based chemotherapy response assay (ATP-CRA).
  
  
  METHODS
  Forty-seven cases of TNBC were included. Immunohistochemical stains for androgen receptor (AR), p53, CD10, c-kit, CK5/6, vimentin, bcl-2, E-cadherin, Ki-67 and epidermal growth factor receptor were performed. In vitro ATP-CRA was used to analyze chemosensitivity for 5-fluorouracil (5-FU), docetaxel, doxorubicin, epirubicin, vinorelbine, gemcitabine, methotrexate (MTX), oxaliplatin and paclitaxel.
  
  
  RESULTS
  The results showed that all cytotoxic agents demonstrated the trend that E-cadherin-expressing cases had a higher cell death rate than E-cadherin-negative cases. Particularly, vinorelbine showed statistical significance (P = 0.004). Cases with AR expression showed higher cell death rates than those without in 5-FU and MTX (P = 0.012 and 0.014, respectively).
  
  
  CONCLUSIONS
  E-cadherin and AR could be candidate predictive factors for chemotherapy response in TNBC. Further in vivo study is required to clarify their roles.
authors.affiliation: Department of Pathology, Yonsei University College of Medicine, Severance Hospital, 250 Seongsanno, Seodaemun-gu, Seoul, South Korea. kjs1976@yuhs.ac
authors.forename: Ja Seung
authors.initials: JS
authors.lastname: Koo
authors.forename: Woohee
authors.initials: W
authors.lastname: Jung
authors.forename: Joon
authors.initials: J
authors.lastname: Jeong
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy / Q000378:metabolism / Q000401:mortality; D000255:Adenosine Triphosphate / Q000378:metabolism; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000378:metabolism*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000378:metabolism* / Q000401:mortality; D015820:Cadherins / Q000378:metabolism*; D018270:Carcinoma, Ductal, Breast / Q000188:drug therapy / Q000378:metabolism / Q000401:mortality; D018276:Carcinoma, Medullary / Q000188:drug therapy / Q000378:metabolism / Q000401:mortality; D016923:Cell Death / Q000187:drug effects; D005260:Female; D006801:Humans; D019394:Ki-67 Antigen / Q000378:metabolism; D008875:Middle Aged; D011237:Predictive Value of Tests; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000378:metabolism; D011944:Receptors, Androgen / Q000378:metabolism*; D016159:Tumor Suppressor Protein p53 / Q000378:metabolism
chemical_list: C410798:AR protein, human; D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D015820:Cadherins; D019394:Ki-67 Antigen; D019253:Proto-Oncogene Proteins c-bcl-2; D011944:Receptors, Androgen; D016159:Tumor Suppressor Protein p53; D000255:Adenosine Triphosphate